Page 142 - Genentech News Today

Extended follow-up from the phase 3 SEQUOIA trial demonstrated that zanubrutinib maintained a progression-free survival benefit compared with bendamustine plus rituximab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

The global Cardiac Monitoring and Cardiac Rhythm Management Devices market size is expected to reach USD 60.25 billion by 2030 and exhibit a CAGR of 6.6%...

The global Recombinant DNA Technology market size is expected to reach USD 274.52 billion by 2030 and exhibit a CAGR of 7.6% in the forecast period...

Two-year study will help experts understand why certain diseases affect some people more than others and why they progress differently in different people

Pancreatic cancer has proven resistant to immunotherapy in the past, but personalized mRNA vaccines may overcome that problem.

WASHINGTON — In patients with idiopathic pulmonary fibrosis, yearly lung function decline rates did not improve with two different dosages of ziritaxestat, according to an American Thoracic Society International Conference presentation.“Unfortunately, ziritaxestat did not improve clinical outcomes compared with placebo in patients with IPF receiving standard of care,” Toby M.

The IRIS Registry, managed and curated by Verana Health’s VeraQ population health data engine, offers researchers and clinicians the opportunity to gather insights on real-world practice patterns, clinical outcomes and more.

The addition of ibrutinib to bendamustine plus rituximab or R-CHOP did not lead to a statistically significant improvement in progression-free survival vs either chemoimmunotherapy regimen alone in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma.

Nitika Parmar (second from left), professor of biology/microbiology at Cal State University Channel Islands, in one of the school's biotech labs with students. (courtesy photo) Two Ventura County higher education institutions recognize the need to prepare students for careers in the burgeoning biotech industry, including the Conejo Valley life sciences hub. Moorpark College will be

The CAR T-cell therapy lisocabtagene maraleucel produced rapid and durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.